bluuebunny/crossref_metadata_2025_split huggingface dataset:
714-P: Greater Improvement in Insulin Sensitivity Per Unit Weight Loss with Tirzepatide Compared with Selective GLP-1 Receptor Agonism
Authors: MATHER KIEREN J. , MARI ANDREA , LI JING , HEISE TIM , DE VRIES J. HANS , URVA SHWETA , COSKUN TAMER , MILICEVIC ZVONKO , HAUPT AXEL , THOMAS MELISSA K. 
Published: May 2022

Tirzepatide (TZP) , a novel GIP-GLP-1 dual agonist, improved fasting measures of insulin sensitivity partially attributable to weight loss in Phase 2 studies. Studies in mice demonstrated that GIP receptor agonism with TZP improved insulin sensitivity independent of weight loss. To further evaluate insulin-sensitizing actions of TZP, we measured insulin sensitivity with hyperinsulinemic euglycemic clamps (M-value) in a 28-week double-blind randomized controlled trial comparing effects of TZP 15mg with placebo or semaglutide 1mg (SEMA) , a selective GLP-1RA, all subcutaneous QW. Linear regression was used to compare relationships of change in M-value versus change in weight across treatment groups. Change in M-value was related to absolute change and % change in weight (Figure) . Slopes of linear relationships with absolute and % weight change differed between TZP and SEMA (absolute change: p=0.015; % change: p=0.03) . Larger negative slopes were observed for TZP compared with SEMA on change in M-value related to absolute change and to % change in weight. These results suggest that TZP may provide greater improvement in insulin sensitivity than a selective GLP-1RA per unit weight loss, most evident in subjects with greater weight loss.

Disclosure
K.J.Mather: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. M.K.Thomas: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. A.Mari: Consultant; Lilly, Research Support; Lilly. J.Li: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. T.Heise: Advisory Panel; Novo Nordisk A/S, Research Support; ADOCIA, AstraZeneca, Biocon, Boehringer Ingelheim International GmbH, Crinetics Pharmaceuticals, Inc., Eli Lilly and Company, Gan & Lee Pharmaceuticals, Genova, Nestlé, Neuraly Inc., Novo Nordisk A/S, Sanofi, Zealand Pharma A/S, Speaker's Bureau; Eli Lilly and Company, Gan & Lee Pharmaceuticals, Novo Nordisk A/S. J.De vries: Advisory Panel; ADOCIA, Novo Nordisk A/S, Zealand Pharma A/S, Speaker's Bureau; Novo Nordisk A/S. S.Urva: Employee; Eli Lilly and Company. T.Coskun: Employee; Eli Lilly and Company. Z.Milicevic: Employee; Eli Lilly and Company. A.Haupt: Employee; Lilly, Stock/Shareholder; Lilly.

Funding
Eli Lilly and Company
715-P: Tirzepatide as Monotherapy Improved Markers of Beta-Cell Function and Insulin Sensitivity in People with Type 2 Diabetes (SURPASS-1)
Authors: LEE CLARE , MAO HUZHANG , THIEU VIVIAN , THOMAS MELISSA K. 
Published: May 2022

Tirzepatide (TZP) , a novel dual GIP/GLP-1 receptor agonist, led to greater HbA1c, fasting serum glucose and body weight reductions vs. placebo (PBO) in people with early T2D (baseline mean T2D duration 4.7 y and 54% no prior diabetes medications) from the 40-wk SURPASS-1 trial. In a Phase 2b trial, TZP also improved β-cell function and insulin sensitivity (IS) vs. PBO and selective GLP-1 receptor agonist, dulaglutide 1.5 mg. Similarly, in SURPASS-1, TZP improved β-cell function, as indicated by a 75-80% increase in HOMA2-B, and insulin resistance, as indicated by a 2-12% decrease in fasting insulin and 8-20% decrease in HOMA2-IR. In this analysis, we aimed to explore changes in additional biomarkers of β-cell function and IS after TZP monotherapy (5, and 15 mg) . At 40 wks, proinsulin/C-peptide ratios, a marker of insulin processing, β-cell stress and β-cell function improved with decrease by 47-49% with TZP vs. -0.1% with PBO (p&lt;0.001, all doses) (Table) . Fasting proinsulin decreased by 49-55% with TZP vs. no change with PBO (p&lt;0.001, all doses) . Decreases in fasting C-peptide by 3-9% with TZP did not differ vs. PBO. TZP vs. PBO improved biomarkers of IS evidenced by increases in adiponectin (16-23% vs. -0.2%; p≤0.028, all doses) and IGFBP-2 (38-70% vs. 4.1%; p&lt;0.001, all doses) . As a monotherapy for early T2D, TZP achieved significant improvement in markers of β-cell function and IS.

Disclosure
C.Lee: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. H.Mao: Employee; Eli Lilly and Company. V.Thieu: None. M.K.Thomas: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company.

Funding
Eli Lilly and Company
717-P: Glycemic Control with Tirzepatide in People with Type 2 Diabetes by Baseline HbA1c =8.5% or &gt;8.5%
Authors: ALEPPO GRAZIA , DE BLOCK CHRISTOPHE , LEVINE JOSHUA A. , GOMEZ-VALDERAS ELISA , BENNEYWORTH BRIAN D. 
Published: May 2022

Tirzepatide, a once weekly GIP/GLP-1 receptor agonist in development for T2D, demonstrated superior glycemic control in the Phase 3 SURPASS clinical trial program. This post-hoc analysis assessed glycemic control with tirzepatide in participants stratified by baseline (BL) HbA1c (≤8.5%, &gt;8.5%) . Mean change from BL in HbA1c was assessed in tirzepatide-treated participants (5, or 15 mg) from SURPASS-1 (monotherapy) , SURPASS-2 (add-on to MET) , SURPASS-3 (add on to MET ± SGLT2i) , SURPASS-4 (add-on to MET, SGLT2i, or sulfonylurea) and SURPASS-5 (add-on to insulin glargine ± MET) at trial endpoints (40 or 52 weeks) . Safety was also presented. Treatment comparisons were estimated using data while participants were on treatment and without rescue medications (efficacy estimand) . Across each SURPASS trial, ranges in mean BL HbA1c were 7.94-8.52%, mean BMI were 31.9-34.2 kg/m2 and mean diabetes duration were 4.7-13.3 years. At trial endpoints, HbA1c reductions from BL ranged from 1.55-2.14% in the BL HbA1c ≤8.5% subgroup and 2.70-3.46% in the BL HbA1c &gt;8.5% subgroup (Table) . Gastrointestinal side effects were similar to those reported in the incretin class and hypoglycemic events (blood glucose &lt;54 mg/dL or severe) were low. In conclusion, significant and clinically meaningful HbA1c reductions were observed with tirzepatide, irrespective of BL HbA1c.

Disclosure
G.Aleppo: Consultant; Insulet Corporation, Research Support; AstraZeneca, Dexcom, Inc., Eli Lilly and Company, Fractyl Health, Inc., Insulet Corporation, Novo Nordisk, Speaker's Bureau; Dexcom, Inc. C.De block: Advisory Panel; Abbott Diagnostics, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Medtronic, Novo Nordisk, Research Support; Indigo Diabetes, Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novo Nordisk. J.A.Levine: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. E.Gomez-valderas: Employee; Lilly, Stock/Shareholder; Lilly. B.D.Benneyworth: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company.

Funding
Eli Lilly and Company
723-P: The Dual Glucagon and Glucagon-Like Peptide-1 Receptor (GCGR/GLP-1R) Agonist BI 4569Reduces Body Weight in Diet-Induced Obese Mice Based on Food Intake Reduction and an Increase in Energy Expenditure
Authors: ZIMMERMANN TINA , THOMAS LEO , BAADER-PAGLER TAMARA , HAEBEL PETER , NEUBAUER HEIKE , SIMON ERIC , REINDL WOLFGANG , BAJRAMI BESNIK , RIST WOLFGANG , UPHUES INGO , AUGUSTIN ROBERT 
Published: May 2022

BI 4569 is a synthetic peptide optimized to simultaneously engage the GCGR and GLP-1R. BI 4569 contains a fatty acid-based half-life extension that supports once-weekly subcutaneous injection in humans, and is currently in clinical investigation in patients with obesity or NASH. BI 4569 activates the human GCGR and GLP-1R in 100% human plasma with a potency (EC50) of 6.3 nM and 1 nM, respectively. BI 4569 potently increases glucose-stimulated insulin secretion from mouse islets (EC50 5.7 nM) and insulin secretion from perifused human islets. On single injection in lean mice, BI 4569 dose-dependently reduced food intake (FI) , gastric emptying (GE) and improved oral glucose tolerance (oGTT) with an ED50 of 90, 41, and 2.1 nmol/kg, respectively. Based on dose-dependent changes in liver NNMT mRNA and plasma amino acids, BI 4569 engages the GCGR, unlike semaglutide. Receptor-specificity of target engagement was further shown in GLP-1R knockout mice (FI, GE, oGTT) . The bodyweight-lowering efficacy of BI 4569 (3, 10, 20, 30 nmol/kg) was compared with semaglutide (20, 100 nmol/kg) in diet-induced obese mice. After 4 weeks of daily dosing, BI 4569 showed a superior bodyweight-lowering efficacy (32% at 30 nmol/kg, p≤0.0vs. vehicle) compared with a maximally effective dose of semaglutide (27% at 100 nmol/kg; p≤0.0vs. vehicle) . This greater bodyweight-lowering efficacy of BI 4569 was associated with changes in GCGR target engagement biomarkers, such as liver lipids, NNMT mRNA, plasma glucagon, FGF21, and cholesterol. Mechanistically, the superior bodyweight-lowering efficacy of BI 4569 was attributed to an increase in energy expenditure (measured at and 20 nmol/kg) .
In summary, the preclinical characterization of the novel dual GCGR/GLP-1R agonist BI 4569 provides strong evidence for its clinical benefit in patients with obesity and associated comorbidities.

Disclosure
T. Zimmermann: Employee; Boehringer Ingelheim Pharma GmbH&Co.KG. L. Thomas: Employee; Boehringer Ingelheim International GmbH. T. Baader-Pagler: Employee; Boehringer Ingelheim International GmbH. P. Haebel: Employee; Boehringer Ingelheim International GmbH. H. Neubauer: Employee; Boehringer Ingelheim International GmbH. E. Simon: Employee; Boehringer Ingelheim Pharma GmbH&Co KG. W. Reindl: Employee; Boehringer Ingelheim International GmbH. B. Bajrami: None. W. Rist: Employee; Boehringer Ingelheim International GmbH. I. Uphues: Employee; Boehringer Ingelheim International GmbH. R. Augustin: None.
726-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Clinical Characteristics and Treatment Pattern Analyses
Authors: GUERCI BRUNO , GIORGINO FRANCESCO , BOYE KRISTINA , FUECHTENBUSCH MARTIN , HEITMANN ELKE , LEBREC JEREMIE , DIB ANNE , FEDERICI MARCO ORSINI , YU MARIA , GARCIA-PEREZ LUIS-EMILIO 
Published: May 2022

TROPHIES was a 24-month, prospective, non-comparative, observational study in adult patients with T2D initiating their first injectable glucose-lowering treatment with once-weekly dulaglutide (DU; N=1,014) or once-daily liraglutide (LIRA; N=991) in France, Germany, and Italy. Secondary objectives included assessments of HbA1c, body weight and treatment patterns. Clinical characteristics of the DU and LIRA cohorts at 24 months are described in the Table. Most patients receiving DU (856/1,014) initiated treatment at 1.5 mg/week and, among 286 patients with a significant treatment change, 237 were still receiving 1.5 mg/week. In the LIRA cohort, most patients (809/991) initiated at the starting dose 0.6 mg/day and 45% increased dose to 1.2 mg/day by Day 90; however, 17% of patients were already receiving 1.8 mg/day by Day 90. At the first significant treatment change 285/448 patients in the LIRA cohort were receiving 1.2 mg/day. Insulin was initiated by 79 and 97 patients in the DU and LIRA cohorts, respectively. Both treatments showed clinically meaningful effectiveness on HbA1c and weight, maintained over the 24-month study period.

Disclosure
B. Guerci: Advisory Panel; Amgen Inc., Medtronic. Board Member; Abbott Diagnostics, AstraZeneca, Bayer AG, Eli Lilly and Company, Novartis Pharmaceuticals Corporation. Consultant; Boehringer Ingelheim International GmbH, Intercept Pharmaceuticals, Inc., Novo Nordisk. F. Giorgino: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk. Consultant; Lilly Diabetes, Sanofi. Research Support; Lilly Diabetes, Roche Diabetes Care, Takeda Pharmaceutical Company Limited. K. Boye: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. M. Fuechtenbusch: Advisory Panel; Berlin-Chemie AG. Consultant; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp. Speaker's Bureau; AstraZeneca, Novo Nordisk. E. Heitmann: None. J. Lebrec: Consultant; Eli Lilly and Company. A. Dib: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. M. Orsini Federici: Employee; Eli Lilly and Company. M. Yu: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company. L. Garcia-Perez: Employee; Eli Lilly and Company. Stock/Shareholder; Eli Lilly and Company.
738-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Patient-Reported Outcomes
Authors: FUECHTENBUSCH MARTIN , GUERCI BRUNO , GIORGINO FRANCESCO , GARCIA-PEREZ LUIS-EMILIO , HEITMANN ELKE , LEBREC JEREMIE , BARRETT ANNABEL , DIB ANNE , FEDERICI MARCO ORSINI , BOYE KRISTINA 
Published: May 2022

Data on patient-reported outcome (PRO) measures in people living with T2D who initiate injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication in routine clinical practice are limited. Here we present final PRO data from the TROPHIES 24-month, prospective, non-comparative, observational study of adult patients with T2D in France, Germany and Italy who started their first injectable GLP-1 RA with either once-weekly dulaglutide (DU) or once-daily liraglutide (LIRA) . Patients’ scores on PRO questionnaires were assessed every 6 months. We present scores at 24 months compared with baseline values before starting DU or LIRA treatment. For each PRO measure, higher scores reflect better outcomes. Baseline characteristics (previously published) for patients prescribed DU (N=1,014) or LIRA (N=991) were similar between groups. Mean changes from baseline to 24 months in PRO scores indicate improvements in health outcomes in patients initiating DU or LIRA (Table) .
In summary, among those patients still evaluable at 24 months we observed improvements in PRO scores from baseline in both groups, but with a more pronounced trend of improvement in the DU cohort for EQ-5D-5L VAS, IW-SP, DTSQs total, and DPM life and work productivity scores.

Disclosure
M.Fuechtenbusch: Advisory Panel; Berlin-Chemie AG, Consultant; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Merck Sharp & Dohme Corp., Speaker's Bureau; AstraZeneca, Novo Nordisk. K.Boye: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. B.Guerci: Advisory Panel; Amgen Inc., Medtronic, Board Member; Abbott Diagnostics, AstraZeneca, Bayer AG, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Consultant; Boehringer Ingelheim International GmbH, Intercept Pharmaceuticals, Inc., Novo Nordisk. F.Giorgino: Advisory Panel; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Consultant; Lilly Diabetes, Sanofi, Research Support; Lilly Diabetes, Roche Diabetes Care, Takeda Pharmaceutical Company Limited. L.Garcia-perez: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. E.Heitmann: None. J.Lebrec: Consultant; Eli Lilly and Company. A.Barrett: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. A.Dib: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. M.Orsini federici: Employee; Eli Lilly and Company.
75-LB: Use of Continuous Glucose Monitoring (CGM) and Its Association with Economic Outcomes in the Real-World Setting
Authors: PEREZ-NIEVES MAGALY , HANKOSKY EMILY R. , FAN LUDI , GELSEY FELICIA , EBY ELIZABETH L. , SIMS TRACY J. , UMEH EMEKA , JUNEJA RATTAN 
Published: May 2022

Background: CGM is increasingly used as tool in the management of diabetes, supporting improvements in glycemic control and quality of life.
Objectives: The aim of this retrospective study was to evaluate the association between CGM use and healthcare resource utilization (HCRU) and cost.
Methods: Using medical claims from Clarivate™ Real-World Evidence repository and CGM data from Glooko®, US people with diabetes (≥18 years) (PwD) and on insulin were assigned to mutually exclusive cohorts based on CGM usage status and matched in terms of age, gender, and diabetes type. First CGM use (index) was required to occur within January 1, 2015 - July 30, 2019. HCRU and costs were assessed 12 months post-index.
Results: After matching, 3,918 PwD were assigned into each cohort. Significantly more CGM vs. non CGM users (p&lt;0.0001) were on insulin pump, treated with bolus insulin only, and commercially insured. Mean pre-index Charlson Comorbidity Index (CCI) scores were lower (p&lt;0.00001) and most diabetes-related comorbidities were less prevalent (p&lt;0.01) in the CGM vs. non-CGM cohort.
After adjusting for demographics, diabetes type, CCI, and insurance, the use of CGM vs. no CGM was associated with a 27-70% and 32-76% reduction in HCRU and costs (p&lt;0.0001) , respectively.
Conclusion: The use of CGM (vs. no CGM use) was associated with lower HCRU and costs, which may result in lower healthcare burden for PwD and payers.

Disclosure
M. Perez-nieves: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. E. R. Hankosky: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. L. Fan: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. F. Gelsey: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. E. L. Eby: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. T. J. Sims: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company. E. Umeh: None. R. Juneja: Employee; Eli Lilly and Company, Stock/Shareholder; Eli Lilly and Company.

Funding
Eli Lilly and Company
76-OR: Macrophage-Derived Proinflammatory Lipids Play a Role in the Development of Type 1 Diabetes
Authors: ALMUTAIRI ABDULAZIZ , WHITE TAYLEUR , STEPHENSON DANIEL , GAI YING , UBIL ERIC , CHALFANT CHARLES , RAMANADHAM SASANKA 
Published: May 2022

Type 1 diabetes (T1D) is a consequence of autoimmune-mediated destruction of pancreatic β-cells, but the leading causes for this process remain elusive. We revealed that Ca2+-independent phospholipase A2β (iPLA2β) , which hydrolyzes membrane phospholipids at the sn-2 position to generate bioactive lipids, modulates polarization of macrophages (MΦ) . Several of the iPLA2β-derived lipid signals (iDLs) are proinflammatory and can initiate immune cell infiltration and β-cell damage. Recently, we showed that production of MΦ- proinflammatory lipids (i.e., PGs, DHETs, LTB4) from spontaneous-T1D prone nonobese diabetic mice (NOD) is high during the pre-diabetic phase. Herein, we examined the impact of bone marrow-derived macrophages (BMD-MΦ) -iDLs on T1D development by generating NOD mice with a conditional reduction in MΦ-iPLA2β (NOD.cMΦ iPLA2 &#120573;; -/- and NOD.cMΦ iPLA2 &#120573;; +/- ) . Our findings reveal that (1) BMD-MΦ from NOD.cMΦiPLA2 &#120573;; -/- or NOD.cMΦiPLA2 &#120573;; +/- are skewed towards an M2 (anti-inflammatory) phenotype, in comparison with NOD BMD-MΦ (2) production of proinflammatory lipids (PGs, DHETs, and TXB2) is significantly decreased in BMD-MΦ from NOD.cMΦiPLA2 &#120573;; -/- and NOD.cMΦiPLA2 &#120573;; +/- (3) selective inhibition of PGE2 or DHETs signaling inhibits NOD BMD-MΦ polarization towards a proinflammatory phenotype M1 (4) selective decrease of iPLA2β in MΦ significantly reduces leukocytes infiltration into the pancreas of NOD mice (5) pancreata from NOD.cMΦiPLA2 &#120573;; -/- and NOD.cMΦiPLA2 &#120573;; +/- mice have significantly higher M2 macrophages and less activated T cells (6) importantly, selective decrease of iPLA2β in MΦ (NOD.cMΦiPLA2 &#120573;; -/- and NOD.cMΦiPLA2 &#120573;; +/- ) significantly reduces T1D incidence in NOD mice. The overall reduced macrophages-proinflammatory lipids is associated with increased M2 macrophages and less T1D diabetes pathogenesis in selective decrease of MΦ-iPLA2β NOD mice. And inhibition of selective macrophages-derived iDLs production can be targeted to counter T1D.

Disclosure
A.Almutairi: None. T.White: None. D.Stephenson: None. Y.Gai: None. E.Ubil: None. C.Chalfant: None. S.Ramanadham: None.

Funding
NIH/NIAID R21 (AI 146743) NIH/NIDDK (R01DK110292) Cell, Developmental, & Integrative Biology (CDIB) , the University of Alabama at BirminghamUAB Comprehensive Diabetes CenterKing Saud bin Abdulaziz University for Health Sciences/ Saudi Arabian Cultural Mission
760-P: Performance of the MiniMed 780G System with the Guardian 4 Sensor—Impact on the First 1,570 Real-World Users
Authors: SHIN JOHN , ARRIETA ARCELIA , CASTAÑEDA JAVIER , CORDERO TONI L. , RHINEHART ANDREW S. , VIGERSKY ROBERT A. 
Published: May 2022

Objective: Since 2021, the MiniMed™ 780G advanced hybrid closed-loop system with the non-adjunctive Guardian™ 4 sensor, that does not require calibration, has been commercially available in Europe. In this study, the real-world glycemic outcomes of the first 1,570 individuals using the system were evaluated.
Methods: Analyses were based on data collected since November 2021 from consenting users (N=1,570) in 15 countries who had ≥days of sensor glucose (SG) data. Glycemic outcomes including the mean±SD of the glucose management indicator [GMI], SG, and 24-hour and nighttime percentage of time spent within 70-180mg/dL (TIR) , at &lt;54mg/dL [TBR54], &lt;70mg/dL [TBR70] and &gt;180mg/dL [TAR180] were determined. The mean±SD of time spent in closed loop and the number of closed-loop exits/week were also assessed.
Results: For 94±11% of time spent in closed loop, users had an SG of 153±18mg/dL, GMI of 6.96±0.41% and TIR of 73.5±10.7%. Their TBR54, TBR70 and TAR180 were 0.11±0.15%, 1.7±1.5% and 24.8±11.0%, respectively. During the night (12AM-6AM) , TIR was 81.5±12.8%, TBR54 was 0.08±0.20%, TBR70 was 1.1±1.7% and TAR180 was 17.5±12.9%. The number of closed-loop exits was 0.8±0.9/week.
Conclusion: MiniMed™ 780G system use with the Guardian™ 4 sensor involved substantial time in closed loop and favorable glycemic control that aligned with the recommended international consensus for continuous glucose monitoring metrics.

Disclosure
J.Shin: Employee; Medtronic. A.Arrieta: Employee; Medtronic. J.Castañeda: Employee; Medtronic. T.L.Cordero: Employee; Medtronic, Medtronic. A.S.Rhinehart: Employee; Medtronic, Stock/Shareholder; Medtronic. R.A.Vigersky: Employee; Medtronic.